ABIONYX Pharma Overview
- Year Founded
-
2005
- Status
-
Public
- Employees
-
49
- Stock Symbol
-
ABNX
- Investments
-
2
- Share Price
-
$1.85
- (As of Friday Closing)
ABIONYX Pharma General Information
Description
Abionyx Pharma is a new generation biotech company dedicated to the discovery and development of innovative therapies for patients without existing or effective treatment. The biotech assets inherited from CERENIS Therapeutics constitute a portfolio of valuable programs for the treatment of cardiovascular diseases and associated metabolic diseases such as NAFLD and NASH as well as an HDL targeted drug delivery platform in oncology, more specifically in Immuno oncology and chemotherapy.
Contact Information
Website
www.abionyx.comCorporate Office
- 33 43 Avenue Georges Pompidou Bât. D2
- 31130 Balma
- France
Corporate Office
- 33 43 Avenue Georges Pompidou Bât. D2
- 31130 Balma
- France
ABIONYX Pharma Timeline
ABIONYX Pharma Stock Performance
As of 13-Nov-2026, ABIONYX Pharma’s stock price is $1.85. Its current market cap is $80.8M with 43.8M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.85 | $1.89 | $1.58 - $5.23 | $80.8M | 43.8M | 146K | -$0.26 |
ABIONYX Pharma Financials Summary
As of 30-Jun-2026, ABIONYX Pharma has a trailing 12-month revenue of $4.52M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 99,370 | 157,716 | 40,700 | 48,491 |
| Revenue | 4,523 | 4,583 | 4,925 | 5,021 |
| EBITDA | (7,458) | (5,280) | (4,667) | (3,686) |
| Net Income | (9,400) | (6,260) | (4,741) | (3,807) |
| Total Assets | 41,832 | 15,405 | 14,090 | 16,398 |
| Total Debt | 1,870 | 4,469 | 2,869 | 3,747 |
ABIONYX Pharma Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
ABIONYX Pharma Comparisons
Industry
Financing
Details
ABIONYX Pharma Competitors (22)
One of ABIONYX Pharma’s 22 competitors is Altimmune, a Formerly VC-backed company based in Gaithersburg, MD.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Altimmune | Formerly VC-backed | Gaithersburg, MD | ||||
| Attune Pharmaceuticals | Venture Capital-Backed | New York, NY | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Regenerx | Formerly VC-backed | Rockville, MD | ||||
| ONL Therapeutics | Venture Capital-Backed | Ann Arbor, MI |
ABIONYX Pharma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ABIONYX Pharma Patents
ABIONYX Pharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2024370626-A1 | Lipid binding protein molecule therapy | Pending | 31-Oct-2023 | ||
| EP-4802279-A1 | Lipid binding protein molecule therapy | Pending | 31-Oct-2023 | ||
| WO-2025093929-A1 | Lipid binding protein molecule therapy | Inactive | 31-Oct-2023 | ||
| AU-2024207875-A1 | Lipid binding protein molecule therapy | Pending | 13-Jan-2023 | ||
| EP-4648788-A1 | Lipid binding protein molecule therapy | Pending | 13-Jan-2023 | A61K38/17 |
ABIONYX Pharma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ABIONYX Pharma Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
ABIONYX Pharma Acquisitions (2)
ABIONYX Pharma’s most recent deal was a Merger/Acquisition with Iris Pharma for . The deal was made on 06-Dec-2021.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Iris Pharma | 06-Dec-2021 | Merger/Acquisition | Other Pharmaceuticals and Biotechnology | ||
| Lypro BioSciences | 08-Nov-2017 | Merger/Acquisition | Drug Delivery |
ABIONYX Pharma ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
ABIONYX Pharma Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Iris Pharma | La Gaude, France | 1989 |
ABIONYX Pharma FAQs
-
When was ABIONYX Pharma founded?
ABIONYX Pharma was founded in 2005.
-
Where is ABIONYX Pharma headquartered?
ABIONYX Pharma is headquartered in Balma, France.
-
What is the size of ABIONYX Pharma?
ABIONYX Pharma has 49 total employees.
-
What industry is ABIONYX Pharma in?
ABIONYX Pharma’s primary industry is Drug Discovery.
-
Is ABIONYX Pharma a private or public company?
ABIONYX Pharma is a Public company.
-
What is ABIONYX Pharma’s stock symbol?
The ticker symbol for ABIONYX Pharma is ABNX.
-
What is the current stock price of ABIONYX Pharma?
As of 13-Nov-2026 the stock price of ABIONYX Pharma is $1.85.
-
What is the current market cap of ABIONYX Pharma?
The current market capitalization of ABIONYX Pharma is $80.8M.
-
What is ABIONYX Pharma’s current revenue?
The trailing twelve month revenue for ABIONYX Pharma is $4.52M.
-
Who are ABIONYX Pharma’s competitors?
Altimmune, Attune Pharmaceuticals, Sangamo Therapeutics, Regenerx, and ONL Therapeutics are some of the 22 competitors of ABIONYX Pharma.
-
What is ABIONYX Pharma’s annual earnings per share (EPS)?
ABIONYX Pharma’s EPS for 12 months was -$0.26.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
